NCT00926757View on ClinicalTrials.gov

Prophylactic Use of Entecavir for Non-Hodgkin's Lymphoma Patients With Resolved Hepatitis B

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Non Hodgkin's LymphomaHepatitis B
Interventions
DRUG

Entecavir prophylaxis

Entecavir 0.5mg daily from day 1 of chemotherapy to 3 months after completing chemotherapy

DRUG

Therapeutic entecavir

Entecavir 0.5cm daily since hepatitis flare and HBV reactivation, till hepatitis remission

Trial Locations (1)

11217

Taipei Veterans General Hospital-Division of Gastroenterology, Division of Oncology, Taipei

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Taipei Veterans General Hospital, Taiwan

OTHER_GOV